Abstract
At present, many vaccine manufacturers in China are focusing on the development of combined vaccines based on diphtheria, tetanus, acellular component pertussis vaccine (DTacP). There are great differences in antibody detection methods and protective evaluation criteria in clinical trials of different manufacturers abroad.This paper is aimed to provide experimental evidence and ideas for the design protocol of clinical trial by comparing the immunogenicity results of different DTacP-inactivated poliovirus vaccines, including seroprotection/seroconversion rates and geographic mean titers measured by various detection methods. Key words: Diphtheria-tetanus-acellular pertussis vaccine; Poliovirus vaccine, inactivated; Vaccines, combined; Immunogenicity
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
